Posters

Modeling the Population Health Impact of introducing a Reduced Risk Product into the Japan market

Djurdjevic, S.; Baker, G.; Iida, T.; Konishi, E.; Lüdicke, F.

Conference date
Jun 15, 2018
Conference name
Global Forum on Nicotine (GFN) 2018
Link to more information
Link to more information
Link to more information
Topic
Summary

To learn more on the research and methods behind this poster, you’ll find a complementary brochure here - or view the poster and brochure together here.

Related Publications

Toxicological risk assessment framework for e-vapor products: From product ideation to product commercialization

E-Vapor Products;Toxicological assessment;E-liquid ingredients

Randomized studies assessing the effect of flavor on pharmacokinetic and subjective parameters for dry and moist nicotine pouches

Nicotine pharmacokinetics;Clinical

Scientific Update June 2025 Issue 21

Harm reduction;Nicotine;Scientific Update;Smoke-free products;Research;Perception and Behavior;E-Vapor Products

Scientific Update October 2025 Issue 22

Smoke-free products;Post-Market Studies and Surveillance Study

Nicotine Pouch Patterns of Use in a 10-Week Prospective Study

Post-Market Studies and Surveillance Study

Evaluating Use Patterns of a Closed Electronic Nicotine Delivery System Among Adults in the United States Who Smoke Cigarettes Daily: 8-Week Actual Use Study

Perception and Behavior

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
​
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.